BioNTech and DualityBio Receive FDA Breakthrough Therapy : v

Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced...

Related Keywords

China , Aizenberg , Baden Wüberg , Germany , Shanghai , United States , Fosun Pharma , Vivian Gu , Genentech , Business Development , Drug Administration , National Cancer Institute , Duality Biologics Suzhou Co , Exchange Commission , Pfizer , Roche Group , End Results Program , World Cancer Research Fund International , Human Epidermal Growth Factor Receptor , Breakthrough Therapy , Chief Medical Officer , Duality Immune Toxin Antibody Conjugates , Hormone Receptor Positive , New Technologies , Duality Biologics , Antibody Drug Conjugate , Private Securities Litigation Reform Act , Cancer Research Fund , Natl Cancer , Cancer Stat Facts , Nasdaq Bntx , Biontech Se , Ntx , Dualitybio , Dc , Fda , Nt323 , Endometrial Cancer , Eb 228 Rmutterkrebs ,